JACOBIO-B

1167
4.1607.86% ( -0.355 )
Delay Closed: Nov 16, 16:08:11

Overview

JACOBIO-B (1167)

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s...

Open
4.315
High
4.330
Low
4.090
Prev. Close
4.515
Volume
1.11M
Turnover
4.68M
Avg Price
4.205
Bid/Ask Ratio
20.00%
Amplitude
5.32%
52wk High
9.290
Volume Ratio
0.33
Turnover Ratio
0.14%
52wk Low
3.980
HK Mkt Cap
3.25B
Market CapHKD
3.25B
P/ETTM
5.50
P/EDynamic
2.35
P/EStatic
--
EPSTTM
0.756
EPSDynamic
1.77
EPSStatic
--
BVPS
1.99
P/B
2.09
HK Shares
782.18M
Dividend YieldTTM
--
DividendTTM
--
Shares
782.18M
Min lot size
300
Currency
HKD

JACOBIO-B Analyst Rating

View more

Forecast & Rating

Aug 26, 2026
Price forecast
HK$9.80135.56%
Forecast & RatingBuy
2analysts
  • Strong buy50.00%
  • Buy0.00%
  • Hold50.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Jacobio-B faded from a higher open to close at HK$4.16, down about 7.9%, after touching HK$4.485 at the 09:30 open and sliding to HK$4.090 by 14:04 BJ; volume was 1.11 million shares worth HK$4.65 million, a turnover rate of just 0.14%, reflecting profit-taking after a licensing-driven run that had lifted the stock 27.42% in a single week. The fundamental backdrop is licensing revenue recognition: Q2 2026 revenue reached HK$422.1 million, up 1,587% year on year, with net profit of HK$346.9 million, an 82.18% net margin and EPS of HK$0.4447. Price still sits below MA20 of HK$4.774 and MA60 of HK$5.516, down 35.2% year to date and 55.22% from the 52-week high of HK$9.29, only 4.52% above the 52-week low of HK$3.98, at PE 5.5x and PB 2.09x. Though the durability of licensing income has yet to be verified in coming quarters.

  2. Nov, 13

    Jacobio-B staged a spike-and-fade session, opening at the day's high of HK$4.995 (up 3.95% from the prior close of HK$4.805) before sliding one-way to HK$4.490 at 15:59 in the afternoon session and settling at HK$4.555, down 5.20% on the day, with only 895,200 shares and HK$4.16 million turnover; a 0.11% turnover rate magnified the move. The selling reflects unwinding of the licensing-driven turnaround trade: the stock had risen 27.42% in a single week and then given back 7.55% the following week, and today extends that same rhythm. Fundamentals contrast sharply with the tape: Q2 2026 revenue of HK$422.1 million, up 1587% year on year, net profit of HK$346.9 million, up 1173%, net margin 82.18%, against a PE of 6.02x and PB of 2.29x; yet the price sits below MA20 of 4.827 and MA60 of 5.535, down 29.05% year to date, 50.97% below the 52-week high of HK$9.29 and only 14.45% above the 52-week low of HK$3.98. Clinical progress on SHP2 and other oncology assets remains the variable to watch.

  3. Nov, 6

    After a roughly 9% pop in the prior session, Jacobio-B reversed course, opening at HK$4.910 — the day's high — then rebounding to HK$4.760 in the afternoon before sliding to a HK$4.615 close at the session low, down 6.2% on HK$4.01 million of turnover and a thin 0.11% turnover rate. The pullback sits awkwardly against the fundamentals: licensing deals swung the company to profit, with Q2 2026 revenue of HK$422 million (+1587% YoY), net profit of HK$347 million (+1173%), an 82.18% net margin, HK$0.4447 EPS, a 6.1x PE against 2.32x PB. Yet the close remains below the 20-day moving average of HK$4.961 and the 60-day of HK$5.575, down 28.12% year to date, 50.32% below the 52-week high of HK$9.29 and only 15.95% above the HK$3.98 low. Though with just HK$4.0 million traded, the session's move rests on very thin liquidity.

  4. Nov, 4

    No fresh company-specific news was available in the supplied feed. The session unfolded alongside recently disclosed Q2 2026 results showing revenue of HKD 422.09 million, up 1587.12% year on year, and net profit of HKD 346.87 million, up 1173.18%. The stock opened flat at HKD 4.50, dipped to HKD 4.49, spiked to HKD 4.88, then recovered to close at HKD 4.73; the latest quote was HKD 4.75, up 5.56% from the previous close of HKD 4.50, with about 980,700 shares and HKD 4.55 million turnover. Q2 net margin was 82.18% and EPS was HKD 0.4447, while market cap stood at HKD 3.72 billion, with PE at 6.28x and PB at 2.39x. The shares remain below MA20 at HKD 5.077 and MA60 at HKD 5.595, are down 26.01% year to date, sit 48.87% below the 52-week high of HKD 9.29 and 19.35% above the 52-week low of HKD 3.98. However, the turnover rate was only 0.120%, and the price has not reclaimed its medium-term moving averages.

  5. Oct, 27

    Jacobio opened flat at HK$4.915, which proved to be the intraday high, then drifted lower through both sessions to close at HK$4.720, down 3.97%, after touching HK$4.640 at 15:46 in the afternoon session on thin turnover of 868,200 shares (about HK$4.08m) and a 0.11% turnover rate. The move sits against strong interim fundamentals: licensing income lifted revenue to HK$422m and net profit to HK$347m at an 82.18% net margin, with net profit up more than 11-fold year on year, and the stock had earlier rallied 27.42% in a single week while drawing institutional interest in JAB-23E73. It still trades below its MA20 of 5.499 and MA60 of 5.596, is down 26.48% year to date and 49.19% below the 52-week high of HK$9.29. Recent gains in innovative-drug names have not carried over, though the session's light volume limits what the pullback signals.

News